Grand News Network

Lumikei Med Appoints Global Advisory Board to Champion Gender Equity in Clinical Research

Lumikei Med announces the formation of its first Global Advisory Board in partnership with the Veblen Director Programme, advancing its mission to champion gender equity in clinical research through inclusive, ethical innovation and expert leadership.

Singapore, Singapore, 16th May 2025 – Lumikei Med, a purpose-led healthcare innovation company focused on advancing gender equity in clinical research, has appointed its inaugural Global Advisory Board in partnership with the Veblen Director Programme.

Historically, women were underrepresented, and often excluded, from clinical research. A 1977 FDA guideline barred most women of childbearing age from early-phase trials, citing hormonal and reproductive concerns. Although reversed in 1993, disparities remain: women are still underrepresented in areas like cardiovascular disease, psychiatric conditions, and cancer, with the gap widest in early-phase trials and among women of colour. Moreover, trial data is not always analysed by sex, limiting understanding of treatment safety and efficacy across genders.

Founded to address these gaps, Lumikei Med works at the intersection of advocacy, education, and ethical innovation to build a more inclusive and effective healthcare system—one that reflects the needs of all women, across all backgrounds.

Through this new board, Lumikei gains access to Veblen’s global network of senior leaders, governance experts, and changemakers. Each member brings experience in healthcare strategy, patient advocacy, and impact-driven leadership to support Lumikei’s mission.

Founded by Rubina GoelLumikei Med was born from a bold vision: to ensure that women’s voices, experiences, and health needs are no longer side-lined in medical innovation. 

Lumikei Med – meaning ‘Light beyond form,’ translating to ‘Healing beyond limits’ – is on a mission to transform the future of healthcare through gender equity. By addressing long-standing gaps in representation, we aim to ensure that every woman, regardless of background, has access to healthcare solutions designed with her in mind. Our focus is on empowering communities, educating stakeholders, and creating partnerships that support a system where everyone is truly seen and served.”
— Rubina Goel, Founder, Lumikei Med

With strategic guidance from the newly appointed advisory board, Lumikei Med is poised to drive systemic change—amplifying its mission globally through cross-sector collaboration and visionary leadership.

Meet the Lumikei Med Advisory Board:

Yerusha Moodley
A global expert in governance, risk strategy, and ESG leadership, Yerusha advises on sustainable, ethical approaches to healthcare transformation and organizational resilience. “I’m honoured and excited to join Lumikei Med, a pioneering organisation transforming clinical research to be more inclusive and representative – with a strong focus on women’s health. I look forward to contributing to a future where women are centred in shaping healthcare.”

Tibor Dudjik
With over two decades of tech leadership experience, Tibor contributes expertise in remote-first operations, strategic scaling, and cross-functional execution to support Lumikei Med’s digital infrastructure.

Lumikei Med’s mission is not only timely – it’s essential. Inclusive trials lead to better science, and better science leads to better care. I’m passionate about ensuring innovation in healthcare includes everyone.”

Rafik Adel Zahy
A seasoned business development executive with deep roots in pharma and healthcare, Rafik brings strategic market insight and partnership-building capabilities to help expand Lumikei Med’s global footprint.

“Diverse representation in clinical trials is not just an ethical imperative but a scientific necessity. I’m excited to support Lumikei Med in creating research and care that reflect the diverse populations they serve.”

Ashley Bird
With a career spanning over 20 years in Life Sciences and MedTech, Ashley offers commercial strategy expertise and a strong commitment to inclusive culture-building.

Lumikei Med’s work is addressing long-standing disparities and driving meaningful change, ensuring that healthcare solutions reflect the needs of all women. I’m proud to support their bold vision.”

 

Why Inclusive Research Matters

Biological differences between sexes significantly influence how diseases present and how treatments perform. Women may metabolize drugs differently, experience distinct side effects, or respond to therapies in unique ways. The historical underrepresentation of women in trials has led to critical data gaps, sometimes resulting in inappropriate dosing or elevated health risks.

Ensuring clinical research reflects the population it serves is essential for developing safe, effective, and equitable healthcare solutions. Lumikei Med is committed to raising awareness, advancing dialogue, and supporting initiatives that drive meaningful inclusion in medical research.

 

About Lumikei Med

Lumikei Med is a mission-led healthcare company advocating for gender equity in medical research. Through advocacy, education, collaboration, and innovation, the organization works to ensure that healthcare reflects and serves everyone. By addressing underrepresentation in clinical trials and championing ethical inclusion, Lumikei Med is building a future where every woman – regardless of background – receives the care she deserves.

 

About the Veblen Director Programme

The Veblen Director Programme equips visionary professionals with the tools and governance expertise to serve on boards that create purpose-led impact. Veblen’s global network enables companies like Lumikei Med to access world-class leadership and scale responsibly through strategic guidance and collaboration.

 

For media inquiries, please contact:

Lumikei Med: info@lumikei.com 
Veblen Director Programme: info@veblendirectors.com

Media Contact

Organization: Financial Media

Contact Person: Franziska Grobler

Website: https://www.financialmedia.group/

Email: Send Email

Contact Number: +6584555350

Address: 51 Goldhill Plaza

City: Singapore

Country: Singapore

Release Id: 16052527921